The clinical study to explore the effects of sodium-dependent glucose co-transporter 2 inhibitors on responses of orexigenic hormone 'ghrelin' in patients with type 2 diabetes
Not Applicable
Recruiting
- Conditions
- type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000014223
- Lead Sponsor
- Wakayama medical university, the first department of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1)Body Mass Index <22 2)an excessive alcohol drunker 3)patients who were added same drugs during the course of the trial 4)patients with severe ketosis, diabetic coma or precoma 5)patients with hepatic dysfunction(child-pugh B or worse) or severe renal dysfunction(eGFR<50) 6)patients with severe infection, perioperative period or severe injury 7)patients with allergy for SGLT2 inhibitors 8)patients with a history of gastrointestinal tract surgery 9)pregnant women or women that may have become pregnant 10)patients determined to be inappropriate by physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method changes in plasma ghrelin level before and after 2-week administration of SGLT2 inhibitors
- Secondary Outcome Measures
Name Time Method changes in glycated albumin,glucagon, leptin, growth hormone, insulin-like growth factor-1, antidiuretic hormone, LDL-cholesterol, HDL-cholesterol,C-peptide immunoreactivity, sodium, body composition, body weight, blood pressure, frequency scale for symptoms of gastroesophageal reflux disease and visual analogue sacle for appetite before and after 2-week administration of SGLT2 inhibitors